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Abstract	 ﾠ
 
  The current FDA process is not well suited for the introduction of enhancement drugs 
that are intended to improve certain aspects of cognition or behavior to a degree beyond what is 
normal.  Even though there are no statutory restrictions against approving these drugs, the 
current positioning of the FDA approval process suggests these types of drugs would have a 
difficult time receiving approval for an indication that covers normal, healthy adults.  However, 
until now the FDA has not had to confront this issue directly, since despite common media hype 
there is little scientific evidence that any drugs are true cognitive enhancers.  That said, scientific 
interest in this area is growing, as is the pace of understanding about the framework of the brain.  
It seems only a matter of time before potently effective cognitive enhancements are developed.  
Once this happens, the current FDA norm of approval for a specific indication, followed by large 
off-label use, could result in many important ethical and safety questions going unaddressed.  
Ultimately, if the FDA is going to satisfy its mission to “promote the public health by promptly 
and efficiently reviewing clinical research and taking appropriate action on the marketing of 
regulated products in a timely manner,” a new framework will need to be developed.  
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 ﾠIntroduction	 ﾠ
 
While humans have been seeking methods to improve their cognitive abilities for 
thousands of years
1, the presence of drugs that have the potential to create instant improvements 
has never been within the grasp of science.  This has made the question of how the government 
should regulate these drugs a largely hypothetical one up until now.  Currently there is a 
substantial gap in Food and Drug Administration (FDA) processes for how to handle a potent 
enhancer when one is designed.  This paper will explore this gap, and the ethical consequences it 
implies if not remedied.  This paper will consist of three parts.  In the first part, the paper will 
discuss what is meant by cognitive enhancers, and what the current state of enhancers is in the 
medical community and in popular culture.  The second part will explore the approval process 
for a new potential enhancement drug.  The third part will look at the ethical and safety issues 
that are unique to enhancement drugs and which are not currently within the FDA approval 
framework.  Ultimately, this paper will conclude that a new framework needs to be explored so 
that these social consequences can be appropriately addressed. 
The	 ﾠRole	 ﾠof	 ﾠCognitive	 ﾠEnhancers	 ﾠin	 ﾠSociety	 ﾠ
 
To get a better idea of how cognitive enhancers as a class will fit within FDA approval 
guidelines, it is helpful to shore up a clearer definition of what exactly constitutes a cognitive 
enhancer.  Experts have given several different definitions to what makes up a cognitive 
enhancer.  One definition is “prescribing medication to normal adults for the purpose of 
                                                              
1 For example, through language, writing, and education. Page 5 of 36 
   
augmenting their normal cognitive or affective function.”
2  Another definition is “the 
amplification or extension of core capacities of the mind through improvement or augmentation 
of internal or external information processing systems.”
3 If applied to top achievers in society, 
this enhancement can thought to take individuals beyond the normal range of ability for the 
human species.
4 
How we define enhancement is important.  One way to conceptualize enhancements are 
on an individual function level.  For example, if a drug improves working memory, it is an 
enhancement.  Another way is to think of enhancement on a macro level.  At this level, 
regardless of a drugs impact of individual capacities, it is only considered an “enhancement” if it 
“promote[s] the flourishing of an individual and those around him.”
5  Some experts argue that 
enhancement drugs should be considered in the “same general category” of self-improvement as 
“education, good health habits, and information technology,”
6 and that “regulatory agencies 
should allow pharmaceutical companies to market cognitive-enhancing drugs to healthy adults 
provided they have supplied the necessary regulatory data for safety and efficacy.”
7 
Subtle definitional differences here could have significant impacts on the role 
government plays in regulating enhancers.  For example, a broad definition of cognitive 
                                                              
2 Dan Larriviere et al., Responding to Requests from Adult Patients for Neuroenhancements, 73 NEUROLOGY 
1406, 1407 (2009). 
3 Nick Bostrom and Anders Sandberg, Cognitive Enhancement: Methods, Ethics, Regulatory Challenges, 15 
Sci. Eng. Ethics 311, 311 (2009). 
4 Torbjorn Tannsjo, Ought we to Enhance our Cognitive Capacities? 23 Bioethics 421, 422 (2009). 
5 Erik Parens, Creativity, Gratitude, and the Enhancement Debate, in Neuroethics 75, 83 (2004). 
6 Henry Greely, Towards Responsible Use of Cognitive Enhancing Drugs by the Healthy, 456 Nature 702, 702 
(2008). 
7 Id. at 705. Page 6 of 36 
   
enhancement is not limited to pharmacological intervention.  Use of computers, education, 
training, and calculators – any sort of teaching in one sense is aimed at cognitive enhancement.
8  
When we think of cognition as a “process an organism uses to organiz[e] information]…and use 
to guide behavior”
9 a great many activities and components of life fit this definition.  For 
example, with the properly designed mental exercises, subjects have been shown to be able to 
enhance their cognitive abilities with regard to working memory.
10  Since enhancements cover so 
many categories, it may not prove to be particularly helpful to think of a single, homogenous 
class of “cognitive enhancers” in terms of regulation.
11  Instead, the specific characteristic of 
each drug should be analyzed to determine how it should be regulated. 
This variation goes to show that there is not much consensus about how cognitive 
enhancers should be treated in relation to other drugs.  When it comes to the FDA’s treatment of 
enhancers, the manner which the agency seems poised to treat them is look at the extent to which 
a drug is intended to bring someone to a normal state of being, or to improve them beyond 
normal.
12 
The	 ﾠCurrent	 ﾠState	 ﾠof	 ﾠCognitive	 ﾠEnhancing	 ﾠDrugs	 ﾠ
 
Drugs currently on the market that have cognitive enhancement potential take a wide 
variety of forms.  Some of the most well known include methylphenidate (MPH) (Ritalin) and 
                                                              
8 Bostrom, supra  note 2, at  312. 
9 Id. 
10 Alexandra B. Morrison and Jason M. Chein, Does Working Memory Training Work? The Promise and 
Challenges of Enhancing Cognition by Training Working Memory, 18 PSYCHON BULL. REV. 46 (2011). 
11 Jayne C. Lucke, Academic Doping or Viagra for the Brain? 12 EMBO REP. 197, 200 (2011). 
12 See discussion in this paper, infra. Page 7 of 36 
   
amphetamine salts (d-AMP) (Adderall), stimulants used primarily for  the treatment of ADHD
13, 
Modafinil (Provigil), a stimulant used primarily for treatment of several sleep disorders
14, and 
Donepezil, used to treat Alzheimer’s disease.
15 There are a number of other potential drugs in the 
research pipeline, targeting a variety of different health indications.
16 
There are also medical devices in use that have shown promise for cognitive 
enhancement.  Transcranial magnetic stimulation (TMS) and transcranial direct-current 
simulation (tDCS), for example, has been shown to improve performance in learning tasks by 
changing the excitability of the cortex of the brain.
17  Both TMS and tDCS directly stimulate the 
brain, through using localized magnetic field pulses in the case TMS and through small electrical 
currents through electrodes placed on the brain in the case of tDCS.
 18 There are many fields of 
interest being explored by the use of TMS and tDCS, with therapeutic uses that are currently 
                                                              
13 M. Elizabeth Smith & Martha J. Farah, Are Prescription Stimulants ‘Smart Pills’? The Epidemiology and 
Cognitive Neuroscience of Prescription Stimulant Use by Normal Healthy Individuals,  PSYCHOLOGICAL 
BULLETIN ¶1 (2011) 
14 Wesensten et al., infra note 37,  238-247. 
15 Martha Farah et al., infra  note 37, at 422. 
16 Tanya L. Wallace et al., Drug Targets for Cognitive Enhancement in Neuropsychiatric Disorders, 99 
PHARMACOLOGY, BIOCHEMISTRY AND BEHAVIOR 130, 130-145 (2011) 
17 See Bostrom supra note 2, at 318 (citing Hummel and Cohen, Drivers of Brain Plasticity, 18 CURRENT 
OPINION IN NEUROLOGY 667-674 (2005) (on the effects of TMS on brain plasticity); Pascual-Leone et at., 
Transcranial Magnetic Stimulation and Neuroplasticity, 37 NEUROPSYCHOLOGIA 207 (1999) (on the ability of 
TMS to improve performance in learning tasks). 
18 Jan-Hendrick Heinrichs, The Promises and Perils of Non-Invasive Brain Stimulation, 35 INT’L J. L. 
PSYCHIATRY 121, 121 (2012) Page 8 of 36 
   
under clinical trial.
19  The simplicity in construction in tDCS has led to a rise of hobbyists 
creating do it yourself models, which raises safety concerns.
20 
Current and future research into cognitive enhancements touches a number of different 
areas. For example, cognitive enhancement may prove beneficial for individuals seeking to 
overcome substance abuse disorders.  A number of individuals with substance abuse problems 
have been shown to have significant cognitive defects.
21  These defects often make it difficult for 
these individuals to execute behavioral changes needed to break their habits.
22  Research is 
progressing in using cognitive enhancers to block troubling memories in PTSD sufferers from 
becoming embedded and pathological, for example by preventing the emotional memories from 
being embedded in the amygdale.
23  Research is also exploring whether drugs can reverse the 
process once traumatic memories get embedded.
24  Cochlear Implants are another device that has 
enhancement potential.  While currently cochlear implants are used to assist people without 
hearing, the device could also be modified and used as an enhancement by people with normal 
hearing by expanding the range and distance of sounds that person could hear.
25 
 
                                                              
19 See Id., listing more than 30 different domains of study for TMS alone, including attention, memory, and 
processing capabilities, among others. 
20 Id. At 122-124. 
21 Kathleen T. Brady, Cognitive Enhancers in the Treatment of Substance Use Disorders: Clinical Evidence, 
99 PHARMACOLOGY, BIOCHEMISTRY AND BEHAVIOR 285, 286 (2011). 
22 Id. 
23 Walter Glannon, Psychopharmacology and Memory, 32 J. MED. ETHICS 74, 74 (2006). 
24 Id at 75. 
25 Henry Greely, Law and the Revolution in Neuroscience: An Early Look at the Field, 42 AKRON L. REV. 687, 
705-706 (2009) Page 9 of 36 
   
Media	 ﾠCoverage	 ﾠof	 ﾠCognitive	 ﾠEnhancing	 ﾠDrugs	 ﾠ
 
  The coverage of cognitive enhancing drugs and stories about use of such drugs has been 
affected by a significant amount of hype.  Stories about student using drugs like Ritalin or 
Adderall off-label as a way to improve their studying has been a frequent topic in the news.
26  A 
recent study found that these stories were inaccurate in multiple ways.
27  Media coverage tended 
to overemphasize the benefits of cognitive enhancements compared to the risks.
28  Also, media 
reports tended to describe cognitive enhancements as something that is “common and increasing 
widespread,” something data about enhancement prevalence does not necessarily support.
29  The 
evidence in these stories tends to be based on anecdotal examples, rather than an appeal to 
scientific studies.
30  This unbalanced coverage has led experts to fear that the public is getting a 
skewed view about the realities of cognitive enhancements.
31 
Scientific	 ﾠStudies	 ﾠof	 ﾠCognitive	 ﾠEnhancing	 ﾠDrugs	 ﾠ
 
Given this coverage in the media, questions about the prevalence and effectiveness of 
these drugs become especially salient.  Either high prevalence or high efficacy of the drugs puts 
pressure on the federal government to come up with consistent standard for how to make sure 
these products are not on the market in an unsafe manner. 
                                                              
26 Partridge, infra note 27. 
27 Bradley Partridge, et al., Smart Drugs “As Common as Coffee”: Media Hype about Neuroenhancement, 6 
PLOS ONE ¶ 4-8, Nov. 2011 
28 Id.  
29 Id. 
30 Cynthia Forlini and Eric Racine, Disagreements with Implications: Diverging Discourses on the Ethics of 
Non-Medical Use of Methylphenidate for Performance Enhancement, 10 BMC MED. ETHICS 9, ¶ 7-8 (2009), 
http://biomedcentral.com/1472-6939/10/9. 
31 Id. at 2.  Page 10 of 36 
 
Studies about the prevalence of use of cognitive enhancers are highly varied.  For 
example, among student populations, studies have shown life-time illicit prescription drug use 
estimates range from 6.9% to 35.3%.
32  A study looking at how often physicians directly get 
requests to prescriptions for drugs they view as enhancements found that 62% of physicians 
received such requests at least monthly, with 12% receiving requests daily.  While physicians did 
not always report agreeing to these requests, 37% still said that they prescribed medicine which 
they view as enhancement at least monthly.
33  
In testing efficacy, there is an overall lack of large clinical studies on the effects and 
safety of cognitive enhancers in healthy people.
34  Most of the studies that exist often have small 
sample sizes, are experimental, and show limited effects.
35  In addition there are safety concerns 
about the long-term effects of cognitive enhancing drugs due to this lack of research.
36 Cognitive 
enhancement is a subject that tends to receive limited research funding, partially because it is so 
difficult for the pharmaceutical industry to get cognitive enhancement as an indication from the 
FDA.
37 
Of the studies that have been performed to see whether various prescription medications 
can improve cognitive enhancement, they tend to have very small population samples, and the 
results are modest and mixed.  Several studies have shown that the use of d-AMP or MPH 
                                                              
32 Id. 
33 Timothy D. Hoetze et al., ‘Doctor, Would You Prescribe a Pill to Help Me…?’ A Notional Survey of 
Physicians on Using Medicine for Human Enhancement, 11 AM. J. BIOETHICS 3, 6-7 (2011). 
34 Larriviere, supra note 1, at 1409. 
35 Bostrom, supra  note 2, at  313. 
36 William P. Cheshire, Jr. Accelerated Thought in the Fast Lane, 25 ETHICS AND MEDICINE 75, 77 (2009). 
37 Smith & Farah, supra note 11, at 20. Page 11 of 36 
 
created some modest benefits in memory recall in normal individuals.
38 However, a number of 
studies also have null results, for example certain studies dealing with working memory and 
cognitive control.
39  In several studies, participants who had lower base scores were the ones 
most likely benefit from use of the medications.
40  Many research questions remained 
unanswered.  For example, sit has not been well studied whether cognitive enhancers can 
improve motivation in individuals.  It is also not well known the extent to which enhancement 
has any impact on improved one’s well being or happiness.
41  But ultimately, the evidence points 
to very modest benefits to healthy individuals from current drugs on the market. 
The	 ﾠFDA	 ﾠApproval	 ﾠProcess	 ﾠfor	 ﾠCognitive	 ﾠEnhancers	 ﾠ
 
New	 ﾠDrug	 ﾠApproval	 ﾠProcess	 ﾠ
 
Drug is a defined term in the Federal Food, Drug, and Cosmetic Act (FDCA). An article 
is considered a drug under the act if it is (i) officially recognized as such by, e.g., the United 
States Pharmacopoeia, (ii) intended for use in the diagnosis, cure, mitigation, treatment, or 
prevention of disease, or (iii) intended to affect the structure or function of the body.
42   
                                                              
38 Id. at 10. 
39 See Id. at 14-17 (2011); See also, Wesensten et al., Maintaining Alertness and Performance During Sleep 
Deprivation: Modafinil Versus Caffeine. 159 PSYCHOPHARMACOLOGY 238-247 (2002) (Modafinil may 
provide no more of a cognitive benefit than caffeine does);  Martha Farah, et al., Neurocognitive Enhancement: 
What can we do and what should we do? 5 Nature Rev. Neuroscience 421, 422 (2004) (“Although Donepezil, 
a cholinesterase inhibitor that is used to treat Alzheimer’s disease, did enhance performance in one study of 
healthy middle-aged pilots after flight simulator training, drug companies are looking elsewhere for 
pharmacological approaches to memory enhancement in normal individuals.”). 
40 Smith & Farah, supra note 11, at 17. 
41 Tannsjo, supra note 3, at 422-27. 
42 21 U.S.C.A. §321(g)(1) (2009). Page 12 of 36 
 
This separates the definition of drugs into different tracks.  The first track is the track 
traditionally thought of – drugs designed to address a disease.  But with definition (iii), the FDA 
clearly has a second carve-out – drugs not intended to diagnose, cure, mitigate, treat, or prevent a 
disease, but to only affect the structure and function of the body.
43   The structure/function track 
of drugs has the potential to cover an extremely broad range of products, including cognitive 
enhancements.   Many products that we use everyday technically affect the structure of our body 
in some way. Courts, however, have attempted to put boundaries on what can be covered by the 
structure function track, so that the product must have a ‘decided’ effect upon the structure or 
function.
44  This definition should cover most potential cognitive enhancers.   
Any new drug brought to the marketplace must first be approved by the FDA through a 
New Drug Application (NDA).
45  New drugs are defined as drugs not currently considered to be 
safe and effective for the proposed by use qualified experts in the field.
46  The NDA approval 
process is very time consuming and expensive, as of 2005 “spanning seven to twelve years and 
frequently costing as much as $400 million.”
47  Courts have held that patients do not have any 
                                                              
43 See James O’Reilly, 1 Food and Drug Admin. § 13:7 (2011); “Structure or function” distinctions are a 
vehicle by which FDA can reach out and touch a product through its benefit claims. 
44 See FTC v. Liggett & Myers Tobacco, 108. F. Supp. 573, 576 (S.D.N.Y. 1952) (distinguishing weight loss 
products from cigarettes in that weight loss products “have very decided effects upon the structure of the body 
and the very purpose for which the product is consumed is to bring about such effects”). 
45 21 U.S.C.A. §355(a). (2010) “No person shall introduce or deliver for introduction into interstate commerce 
any new drug, unless approval of an application filed pursuant to subsection (b) or (j) of this section is 
effective with respect to such drug.” 
46 21 U.S.C.A. §321(p)(1) (2009). 
47 Fox, infra note 48, 1161.  Page 13 of 36 
 
rights to purchase drugs before they are proven effective, even when the patients are suffering 
from dire illness.
48   
The NDA process only looks at approving the exact intended use claimed by the 
manufacturer.
49  However, the NDA process is not limited to drugs that have an indication to 
treat or cure a disease.  In addition to drugs intended to treat diseases, the FDA has also approved 
many drugs that seek to improve “non-life-threatening, non-acute, non disease human 
conditions.”
50  For example, the FDA has approved cosmetic uses of Botox Botulinum Toxin, 
and has approved the height growth hormone Humatrope for use in children with short stature 
but no underlying disease.
51 
With Humatrope the approval was limited to patients at least 2.25 standard deviations 
below mean height.
52  This deviation was far enough from the mean that all parties were 
comfortable that it was highly unlikely that the indicated children would catch up to their peers 
                                                              
48 United States v. Rutherford, 442 U.S. 554, 551 (1979), Abigail Alliance for Better Access to Developmental 
Drugs v. Von Eschenbach, 445 F.3d 470, 472 (D.C. Cir 2006), See also Bernstein, infra note 76, at 1065. 
49 Warner-Lambert Co. v. Apotex Corp., 316 F.3d 1348, 1356 (Fed. Cir. 2003) (holding that “The FDA does 
not grant across-the-board approval to market a drug.  Rather, it grants approval to make, use, and sell a drug 
for a specific purpose for which that drug has been demonstrated to be safe and efficacious”). 
50 Drew Fox, Safety, Efficacy, and Authenticity: The Gap between Ethics and law in FDA Decisionmaking, 
2005 MICH. ST. L. REV. 1135, 1137 (Winter 2005). 
51 See Approval Memo, Botulinum Toxin Type A Product Approval Information - Licensing Action 4/12/02,  
http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/A
pprovalApplications/TherapeuticBiologicApplications/ucm088280.pdf  (accessed May 2
nd, 2012);  Medical 
Review for Application Number: NDA 19-640/S-003, Center For Drug Evaluation and Research, July 25, 
2003, available at: 
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/019640_S033_HUMATROPE_AP.pdf (accessed 
May 2nd, 2012. 
52 Endocrinologic and Metabolic Drugs Advisory Committee Meeting.  Department of Health and Human 
Services; Food and Drug Administration.  June 10, 2003. 
http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3957T1.pdf . (Accessed May 2nd, 2012). Page 14 of 36 
 
in height, and that their stature could have lifestyle difficulties on them.
53  So the Committee 
made it a characteristic of their chosen group’s indication that treatment will only be enough to 
help bring them back to normal – not make them taller than average.  This is similar to the 
diagnosis process for ADHD.  The diagnosis of ADHD is on a scale basis; if a child’s score on 
various attention questions is sufficiently below the mean then they have a clinical diagnosis and 
are eligible for medication to bring them back to a normal state, while individuals not below the 
mean are not approved for treatment in this way, even if they may benefit.
54 
 This suggests that while manufacturers working with cognitive enhancers do not 
necessarily need to find a disease indication for their drug, they will have to show it is effective 
in bringing people to normal who have an otherwise degraded trait.  This distinction points to 
how the FDA might be expected to approach coming cognitive enhancements.  Cognitive 
enhancers that are aimed at normal people in trying to make them better than normal do not fall 
within the framework the FDA is currently working on, and so for these drugs it seems like there 
will be significant resistance by the agency in granting approval. 
The	 ﾠGrowth	 ﾠof	 ﾠNumber	 ﾠof	 ﾠDiseases	 ﾠIndications	 ﾠ
 
If a distinction is to be drawn between enhancements from medicines intended to cure 
diseases, this requires an understanding of what is meant by a disease state.  However, even 
among medical experts distinguishing between disease and non-disease states is not always 
easy.
55  The FDA defines a disease, in terms of dietary supplement claims, as either damage to an 
organ, part, structure, or system of the body such that it does not function property, or a state of 
                                                              
53 Id. 
54 Swanson infra note 127, at 742-746. 
55 Larriviere, supra note 1, at 1407. Page 15 of 36 
 
health leading to such dysfunctioning.”
56  Medical dictionaries define a disease as “a definite 
pathological process having a characteristic set of signs and symptoms.”
57  
Many illnesses are defined by reaching a threshold based on having a certain number of 
symptoms, without a bright line distinction between a health person and an ill one.
58 These 
thresholds vary at different locations around the country.  Patients will find significant 
differences in the types and numbers of symptoms that recognize a diagnosis of ADHD, for 
example, as well as difference in the frequency of stimulant medication to treat the disease.
59 The 
existence of a threshold can make distinguishing between treatment and enhancement difficult 
requiring separating out disorders “rooted in the body and those rooting in the mind or social 
norms.”
60  However, whether something is or is not a disease state to any individual patient will 
depend on that person’s “subjective experiences [and] socio-cultural values” and some feel that 
means the distinction has no clarity when thinking about potential enhancements.
61  An 
alternative way society could frame the question is whether a treatment can improve quality of 
life with benefits that outweigh the costs in terms of health risks and resource consumption.
62    
                                                              
56 21 C.F.R. §101.93(g)(1) (2012). 
57 Dorland’s Medical Dictionary 
58 Hyman, infra note 90, at 596 (2011). 
59 Id. 
60 Marc Jonathan Blitz, Freedom of Thought for the Extended Mind: Cognitive Enhancement and the 
Constitution, 2010 WISC. L. REV. 1049, 1064 (2010). 
61 Matthis Synofzik, Ethically Justified, Clinically Applicable Criteria for Physician Decision-Making in 
Psychopharmacological Enhancement, NEURORETHICS 89, 91 (2009).  Synofzik uses as an example flight 
phobias. 
62 Id. Page 16 of 36 
 
This involves an “operational definition of wellness must be in relation to the demands and goals 
of society, here and now.”
63 
With mental illness, there has been continual expansion of the number of traits that 
qualify as diseases under the (DSM-IVR).
64  In conjunction with the expansion, society has come 
to treat attributes that were previously considered normal – like shyness or attention deficit – as 
diseases deserving medication.
65  Without making a judgment on the positive or negative ethics 
associated with this expansion, the effect of the expansion is that there are a larger number of 
indications available for the pharmaceutical industry to latch on to.  This expansion has proven 
profitable in many instances, such as in the treatment of depression.  In the two decades after 
Prozac was approved, the percentage of the U.S. population receiving medication for the 
treatment of depression increased by  greater than five times to 5% of the population.
66  As the 
disease categories continue to expand, many cognitive enhancers could seek approval under 
framework of these new diseases, and then see wider off-label use. 
A concern is that the growth in the number of conditions considered to be diseases and 
the subsequent growth in medication could lead to an environment where medical intervention is 
seen as the only solution.  This could leave out non-medicine based therapy approaches which 
                                                              
63 Forlini and Racine, supra note 28, at 9 (citing P. KRAMER, LISTENING TO PROZAC, (Penguin Books) (1997)). 
64 Schermer et al., infra note 85 (“Since the first edition of the American Psychiatric Association’s Diagnostic 
and Statistical Manual was published in 1952, more than four hundred new categories of mental illness have 
been conceived”).  One recently introduced diagnosis is ‘mild cognitive impairment,’ typically used for pre-
Alzheimer’s patients.  No drugs have been approved for this indication yet.; See also Synofzik, supra note 59. 
65 Toine Pieters & Stephen Snelders, Psychotropic Drug Use: Between Healing and Enhancing the Mind, 
NEUROETHICS 63, 70 (2009) 
66 Id. at 71.  Page 17 of 36 
 
could have fewer side effects.
67  However, non-medical therapies are still used to help with 
traditional medical conditions, so they would not likely disappear. 
How	 ﾠDoes	 ﾠthe	 ﾠFDA	 ﾠDetermine	 ﾠwhat	 ﾠis	 ﾠan	 ﾠ“Effective”	 ﾠDrug?	 ﾠ
 
The FDCA does not define what is meant by “effective,” and courts have held that the 
interpretation of the phrase is thus left up to the FDA to define.
68  The FDA considers a drug to 
be effective when “there is a general recognition among experts, founded on substantial 
evidence, that the drug in fact produces the results claimed for it under prescribed conditions.”
69  
To be ‘effective’ is not a requirement to cure a disease as long as the treatment meets the 
“sponsor’s claims of prolonged life, improved physical condition, or reduced pain.”
70  Efficacy is 
shown by the manufacturer submitting “substantial evidence” that the drug “will have the effect 
it purports or is represented to have under the conditions of use prescribed, recommended, or 
suggested.”
71  Substantial evidence is further defined as: 
Evidence consisting of adequate and well-controlled investigations, including clinical 
investigations, by experts qualified by scientific training and experience to evaluate the 
effectiveness of the drug involved, on the basis of which it could be fairly and 
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responsibly be concluded by such experts that the drug will have the effect it purports or 
is represented to have under the conditions of use prescribed.
72   
The plural use of “investigations” means that at least two well-controlled studies are needed to 
show a drug’s effectiveness.
73   
The FDA has interpreted substantial evidence as requiring something than “mere 
statistical significance,” to instead show “clinical significance.”
74  Having clinical significance 
means that the nature of the function, in addition to existing, has to be something medically 
beneficial.
75  If a manufacturer seeks approval only on a structure function claim, and not for the 
treatment of a disease, they must still show that the drug has some medical benefit.
76 Clinical 
significance, on the other hand, does not mean something has to be more likely than statistical 
significance.
77  In fact, a large fraction of people who take prescription drugs are not helped by 
                                                              
72 21 U.S.C.A. §355(d) (2010). 
73 Warner-Lambert. v. Heckler, 787 F.2d at 150-51. 
74 Id. 
75 Id.  The purpose was so Congress could ensure that physicians had accurate information about the usefulness 
of drugs, something that was growing increasing difficult given the volume of new drugs reaching the market. 
76 See E.R. Squibb and Sons, Inc. v. Bowen, 870 F.2d 678, 680-682 (D.C.C. 1989).  The FDA held that in 
addition to having an effect indicated on a label, to be “effective” the claimed effect must have “some medical 
significance.”  Squibb pointed to language in 21 U.S.C. 355(d) which defines substantial evidence as requiring 
that “the drug will have the effect it purports or is represented to have.”  Squibb felt that this language 
mandated that the FDA approve the drug as long as it was safe and did what the label purported it did.  The 
court disagreed, holding that Congress did not mean “to eliminate any requirement of efficacy in the sense of 
medical benefit” in drugs, even those only making structure function claims. 
77 Id. at 155. Page 19 of 36 
 
them.  Drugs for the treatment of Alzheimer’s disease benefit only about one in three patients, 
and cancer drugs work for about one in four.
78 
Off-ﾭ‐Label	 ﾠUse	 ﾠof	 ﾠCognitive	 ﾠEnhancers	 ﾠ
 
Once a drug is approved for one purpose the FDA will not seek to prevent a physician 
from prescribing that drug for any off-label indication that the physician in her judgment sees 
fit.
79  The FDA has long held that it not involved in the practice of medicine
80 and Courts have 
affirmed that Congress’ intent in the FDCA was not to “interfere with physicians’ treatment of 
their patients.”
81  New uses are often found after FDA approval, and Congress did not want to 
constrain physicians from putting existing drugs to that new use until a new indication could be 
approved.
82 
Prevalence	 ﾠof	 ﾠOff	 ﾠLabel	 ﾠUse	 ﾠ
	 ﾠ
Studies have shown that once a drug is approved for one intended use there will be a 
dramatic increase in off-label sales.
83 Off-label use is widespread in the United States. A 2003 
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study estimated that off-label uses accounted for between 25 and 60 percent of all prescriptions 
in the United States.
84  A separate 2006 study indicated that there were more than 150 million 
prescriptions for off label drugs in 2001, a majority of which has little or no scientific support in 
regard to their safety or effectiveness.
85  There is a “staggering” amount of off-label use of 
Provigil,
86 with estimates as high as 90% of total prescriptions being off-label.
87 
Patients are often unaware when being prescribed a drug that is it being prescribed off 
label, or even that physicians are allowed to prescribe off-label.
88  Also, there is no informed 
consent requirement that mandates physicians tell a patient that a particular prescription is for an 
off-label use.
89 Often, the physician herself it not able to distinguish between on and off label 
uses.
90 One study found that nearly half the time physicians were unable to correctly identify the 
FDA status of drugs for particular indications – basically a coin flip.
91  In fact, most psychotropic 
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drugs are prescribed by generalist physicians with “little training about their effects or side 
effects and little time to monitor for dosage escalation.”
92 
The prevalence of off-label and the uninformed nature of both patient and physician 
creates a concern.  Because off-label uses are profitable, and the costs associated with getting 
off-label uses formally approved may not be recoverable, drug companies may not have any 
motivation to continue to research a drug’s safety or efficacy once a single indication is found.
 93 
For physicians, while they do not have to fear liability from the FDA for off-label uses, “state 
tort law, including products liability and medical malpractice laws” can serve as a source of 
liability.
94  However, a recent article noted that there are very few medical malpractice cases 
dealing with the off-label prescription by a physician.
95 
It is not necessarily difficult for an individual to find a physician to prescribe off-label 
medications.  The existence of a patient-doctor relationship is created based on mutual agreement 
between the parties, and does not depend on the existence of a disease state.
96  Therefore, if a 
patient is refused an off-label prescription by a physician, they remain free to shop other doctors 
until they find a physician who will provide them with the medication.
97  Even if physicians feel 
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their patients may be engaging in prescription abuse, they are often not comfortable talking to 
their patients about that abuse.
 98 
There is a model in place to deal with prescription standards for drugs that pose risks to 
patients – the Controlled Substances Act.
99  Certain potential cognitive enhancers, such as 
Modafinil, are also classified under the Controlled Substances Act.  This puts an additional 
burden on the physician to only prescribe the drug a) for a legitimate medical purpose and b) in 
the course of professional practice. This begs the question of whether prescribing cognitive 
enhances to healthy individuals constitutes a “legitimate medical purpose.” However, one should 
be skeptical about relying on the use of the Controlled Substances Act to stem the use of 
cognitive enhancement drugs.  Both the high level of illegal drug use, as well as the extreme 
levels of off-label Provigil use suggest that this model would be a limited option for controlling 
cognitive enhancement use. 
Marketing	 ﾠOff-ﾭ‐Label	 ﾠUses	 ﾠ
 
Although off-label use is allowed, manufacturers cannot market the off-label use of their 
drugs. It does not matter whether statements of a company are truthful or not if their speech is 
intended to promote an off-label use.  Any promotion is strictly liable as a violation of the Act.
100 
It can be prosecuted even if the manufacturer had no idea they were promoting an unintended 
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use.
101  The prevention of off-label marketing is one of the only tools available to the FDA to 
prevent bad behavior on the part of drug manufacturers in regard to unapproved uses.
102  It has 
been an active area of enforcement as well.
 103  Even when manufacturers are delivering 
information in the form of “non-promotional speech”, those conversations have still shown to 
often include biased presentations.
104  The off-label use of enhancements “presents an 
inescapable conflict of interest for scientists, manufacturers, and physicians among competing 
incentives for consumer health on the one hand, and socioeconomic gain on the other.”
105 
Off-label marketing can be especially problematic when it comes to cognitive 
enhancement drugs.  Because enhancements do not target a specific subsection of the population 
with a particular disease, there is the potential of immense demand for the product.
106  On the 
other hand, manufacturers have become increasing wary of prosecution for off-label uses.  Part 
of this fear derives from the fact that the FDA can prosecute based on what the “intended use” of 
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a product is, based on the company’s “objective intent.”
107  Based on this theory, if the 
manufacturer has “subjective knowledge” that product is being used primarily in an off-label 
way then the FDA could decide that the intended use of the drug has changed to the unapproved 
use, subjecting the manufacturer to liability.
108  Therefore, a strict reading of this law means a 
manufacturer would have to relabel their drug any time “the manufacturer knows, or has 
knowledge of facts that would lead it to know, that a device introduced into interstate commerce 
by the company is to be used for conditions, purposes, or uses other than those for which the 
company offers it.”
109  While the FDA does not appear to be enforcing this provision against 
makers of current enhancement drugs, the FDA has gone after some companies under this 
theory, for example the makers of billary stents.
110  The fact that Provigil is used up to 90% of 
the time off-label paints a target on this class of drugs for expanded FDA enforcement. 
How	 ﾠShould	 ﾠthe	 ﾠFDA	 ﾠBalance	 ﾠthe	 ﾠBenefits	 ﾠand	 ﾠHarms	 ﾠof	 ﾠCognitive	 ﾠ
Enhancers?	 ﾠ
 
When physicians prescribe drugs for off-label cognitive enhancing uses, it warps the 
typical risk benefit ratio that the agency considered.  Normally this ratio is based on the benefit 
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of curing a state of disease, and that can be balanced against the safety risks the drug contains.  
With any off-label use of a drug there is a risk that the physician or patient may not appreciate 
the level of risk associated with using the drug compared with the unknown benefits when using 
it off-label.  It is often the case that drugs tested for serious diseases end up being used more and 
more by patients affected by less serious conditions.
111 
These concerns, however, are magnified in the case of a healthy individual using drugs 
off-label for cognitive enhancement.  When using a drug off-label to attempt to cure a disease the 
drug was not intended for, the potential for benefit might be unknown or reduced, however the 
magnitude of that benefit should the drug work is still clear.  With cognitive enhancements, the 
nature of the benefits are subtle and it is not as clear how one should balance those benefits 
against safety risks.
112  One possibility, suggested by Kesselheim, is that the FDA could allow 
different scaled levels of promotion of off-label uses, based on which off-label uses the FDA 
feels are deserving of “greater regulatory attention.”
113  This could allow manufacturers to 
participate in scholarly conferences or public medical journal articles on off-label uses without 
being required to begin a sNDA.
114 Since there is so much off-label use occurring anyways, 
greater participation by the manufacturers could help insure that physicians have a better 
understand the nature of the benefits and risks of off-label uses. 
  Another possibility is that the FDA could create a new category of regulation for 
“potential enhancement products: prescription drugs and devices with prospective or confirmed 
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applications independent of ‘use in the diagnosis, cure, mitigation, treatment, or prevention of 
disease.”
115  Doing so, the FDA could go beyond the typical safety and efficacy framework to 
also consider “individual and social values and social consequences when making approval 
determinations.”
116 
What both of these tactics having common is an appreciation that there are some 
individual social consequences of cognitive enhancers that are not well captured by the FDAs 
current approval process.  The next portion of this paper will look at what some of these 
individual and social consequences might be. 
Individual	 ﾠand	 ﾠSocial	 ﾠTradeoffs	 ﾠof	 ﾠCognitive	 ﾠEnhancers	 ﾠ
 
Cognitive	 ﾠEnhancements	 ﾠWill	 ﾠLikely	 ﾠInvolve	 ﾠCognitive	 ﾠTradeoffs	 ﾠ
 
Early research with cognitive enhancers suggests that their benefits are often offset by 
cognitive impairments in other areas. Cognitive enhancers could improve intelligence, for 
example, but at the same time create personality drawbacks, due to how closely cognitive and 
emotional processing are tied in the brain.
117  What has been called cognitive enhancements may 
often be better thought of as cognitive tradeoffs. 
Take the example of memory.  One current medical theory is that our memory functions 
such that it has “optimal levels.”
118  If we improve memory “storage,” we may lose effectiveness 
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in memory “retrieval.”
119  If we take an enhancement that increases our ability to memorize long 
strings of numbers, we may have a hard time forming long term memories.  Memories are stored 
in complex pathways that are still not well understood by science.
120  While we may know how 
to activate one part of the brain; and that an activation correlates to improved performance for 
one indication, we have a hard time figuring out which indications will be harmed by the same 
activation.  Living evidence of the trade-offs associated with cognitive improvement can be seen 
in the performance of savants.
121  Studies have shown that an ideal amount of attention to a task 
requires balancing between too much and too limit focus.
122  A savant has too much focus on one 
thing, hindering attention in general.  The existence of these tradeoffs suggests that “researchers 
need to cast a wide net” to insure that they are collecting all the data needed to balance both the 
benefits and the trade-offs.
123 
Yet, frequently the nature of these tradeoffs is unclear.  For example, early evidence has 
suggested that the use of Adderall in individuals does not represent a tradeoff between cognitive 
function and creativity, as was previously suspected.
124  
Post-approval monitoring by the FDA also becomes more important with cognitive 
enhancers.  The current post-approval surveillance of medicines has been criticized as “having 
limited effectiveness, limited stakeholder participation and a lack of transparency and 
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legitimacy.”
125  Perhaps the FDA should consider its post-approval monitoring limitations when 
making decisions about the cost-benefit tradeoff of approving a drug for an indication.   
Cognitive	 ﾠEnhancements	 ﾠCould	 ﾠBe	 ﾠAddictive	 ﾠ
 
  The concern for addiction is often a focus when the media considers the impacts of 
cognitive enhancers.  Part of the reason people today are especially suspicious about cognitive 
enhancers may be that currently they are mostly all forms of stimulants, which had an 
uncomfortable connection with illegal drug use.
126  Not only is there that connection, but because 
they are stimulants, they do have non-trivial addiction statistics.  A recent study estimated that 
about 10% of individuals partaking in non-medical use of stimulants had become dependent on 
them.
127  More than 11 million prescription medications were thought to have been diverted to 
non-medical use in 2008.
128  Beyond stimulants, part of what can make certain drugs addictive is 
their ability to change the cognitive tradeoffs that one’s brain makes. Since that is a suspected 
problematic indication of to-be-discovered cognitive enhancers, it could give reason to be 
suspicious about whether future cognitive enhancers will also be addictive. 
	 ﾠ Cognitive	 ﾠEnhancement	 ﾠTesting	 ﾠCarries	 ﾠTroubling	 ﾠConsent	 ﾠIssues	 ﾠ
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When someone undergoes behavioral changes when undergoing experimental cognitive 
therapy, the nature of their consent is affected.
129  Even if the patient states that they are 
continuing to consent as they undergo changes, there is a question of what that consent means, 
since the individual is under an altered state.  Cognitive enhancers don’t just change the thoughts 
that we have; they can also cause one to change their behavior.
130  It becomes impossible to 
know whether the individual would be consenting if they were in a normal state of mind, or if 
their consent is only a result of the behavioral change.  This is especially true if a proper 
evaluation of drug takes an extended period of time. The concern is also heightened if the 
procedure produces unexpected results, which happens quite often with cognitive 
enhancements.
131  
A	 ﾠCognitive	 ﾠEnhancement	 ﾠRestriction	 ﾠis	 ﾠa	 ﾠRestriction	 ﾠof	 ﾠOne’s	 ﾠFreedom	 ﾠof	 ﾠMind	 ﾠ
 
With any restriction regulators should be considering the balance between the risks of 
harm of the drug and the danger in restricting one’s “freedom of thought.”
132  Cognitive 
enhancement touches on a fundamental issue that is not present in many other activities limited 
by legislation – one’s “freedom of mind.”
133  It can be argued that using cognitive enhancement 
to change our brain function is an extension of a citizen’s right to have “the power to make 
autonomous choices about the shape of self that perceives, learns, archives, and re-imagines the 
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world.”
134  One way to test this argument is to consider whether we want cognitive enhancers to 
play in a role in helping people with moral defects to earnestly want to take medication to help 
themselves.  Call it alcoholism, or any number of other social moral defects. Should it matter 
whether a morally corrupt person has a known pathological cause behind their weaknesses when 
deciding whether to prescribe a cognitive enhancer to his indication?  If not, then that strongly 
suggests that a greater number of people should have access to enhancers in order to exercise 
control over their mind to better themselves. 
Cognitive	 ﾠEnhancements	 ﾠCan	 ﾠAlso	 ﾠTreat	 ﾠExisting	 ﾠDiseases	 ﾠ
 
If society pushes too far against medications that improve cognition, it could mean that 
drugs are withheld that could benefit people with actual disease conditions.  After all, if 
medications get to the point that they can enhance normal behavior, then that means they will 
likely treat a number of currently out-of-reach disorders.
135  The current system works well for 
avoiding this problem in many cases.  The FDA is not typically considering the likelihood of off-
label uses when they are deciding whether a drug is safe and effective for a specific medical 
indication.  Since there are a large number of specific indications available to target, 
pharmaceutical companies and the FDA can hone in very specific on indications as intended 
uses, covering a plethora of disease states. 
Cognitive	 ﾠEnhancements	 ﾠCould	 ﾠWiden	 ﾠSocietal	 ﾠInequalities	 ﾠ
 
  If access to cognitive enhancers is limited to a specific class of people, then an argument 
against allowing cognitive enhancers is that a narrow group of people could have an unfair 
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advantage over the rest of the populace who cannot afford or are not allowed to obtain cognitive 
enhancers.  Cognitive enhancers could further spread the gap between the haves and have-nots.  
That said, it is worth noting that the default state is not a level playing field.  Genetics and 
environmental upbringing lead to very different opportunities for education and learning.
136  So 
while the FDA might not want to exacerbate a gap, gaps in opportunities are nothing new to 
society.  Also, access to cognitive enhancers could also have the opposite effect.  If made widely 
and affordably available to the poor or uneducated, then these people could have a greater chance 
of getting ahead in society, in effect leveling the playing field. 
Cognitive	 ﾠEnhancement	 ﾠCould	 ﾠbe	 ﾠConsidered	 ﾠBeyond	 ﾠthe	 ﾠGoals	 ﾠof	 ﾠMedicine	 ﾠ
 
The traditional goals of medicine have been expressed as including the physicians 
obligations to “1) prevent and diagnose disease or injury; 2) cure or treat the disease/injury; 3) 
reduce suffering or, if that is not possible, help patients to cope with a disease or injury; 4) 
educate patients about disease/injury and prognosis; 5) help patients to die in peace and with 
dignity; 6) reassure the “worried well” who do not have a disease/injury.”
137 These goals suggest 
that the use of enhancements might be considered to be something that is beyond the bounds of 
medical institutions altogether. 
However, according to some modern medicine has “stripping off its traditional disease-
oriented focus” and has instead moved to a doctor-patient relationship focused on improve the 
“subjective well-being” of a patient.
138  If the is the accepted framework, then it would be 
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practical for physicians to take an active role in the determining whether cognitive enhancers are 
something with which a patient can improve their well being.  
Cognitive	 ﾠEnhancement	 ﾠis	 ﾠseen	 ﾠby	 ﾠsome	 ﾠas	 ﾠan	 ﾠInauthentic	 ﾠForm	 ﾠof	 ﾠPlaying	 ﾠ‘God’	 ﾠ	 ﾠ
 
As one author points out, there is a paradox in thinking about using cognitive enhancers 
to push the limits of human bounds.  On the one hand, our limitations can be considered a 
“fundamental aspect” of what it means to be human.
139  Chasing ever greater performance is a 
form of hubris: playing at being God.
140  Given the complexities of the brain, this hubris could 
have significant negative consequences.  It can also be seen as a rejection of what humans have 
been given – deciding that human nature is not good enough.
141 
Yet on the other hand, it could also be said that it is human nature to want to constantly 
move beyond our limitations.
142  Under this frame, enhancements are less about rejecting 
humanity but instead embracing the most sophisticated progress that humanity has to offer.  If 
bettering oneself through devices foreign to oneself cheapens human nature, than many of the 
great inventions throughout human history also cheapened human nature by their ability to move 
us beyond what we can accomplish with our own hands.  Cognitive enhancers are drugs that 
have been made by man, after all.   
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Cognitive	 ﾠEnhancement	 ﾠSends	 ﾠa	 ﾠMessage	 ﾠAbout	 ﾠHuman	 ﾠInadequacy	 ﾠ
 
The use or diagnosis of a cognitive enhancer sends a statement about one’s self.  The 
context of the use invokes ‘meaning’ about an individual, even if that is not the intention.  If 
HGH is given to a child in the desire that the child be taller, inherent within that message is that 
there is something wrong with them if they end up short.
 143  Two negative messages can come 
out of this.  First, the fact that they have to take an enhancer in the first place can invoke a 
feeling that one is broken.  This is especially true in the case of cognitive enhancers, where a 
reliance on one is essentially acquiescing to the idea that some things are beyond our mental 
capacity to change; that one is helpless to improve without external help.  Second, if an enhancer 
is ineffective, it can heighten the anxiety that person feels about their disability.  For example, in 
the case of ADHD, one problem people could point to that exacerbates the disease is societies’ 
ever growing demands on individuals to perform to the higher standard.
144  These concerns over 
our external image has led some to argue that are moving ever toward a society where a people 
take on a ‘looking glass perspective’, seeking wellness by becoming an “optimal self.”
145  
However, such a pursuit can lead to a creeping loss of one’s identity.  Individuals lose the ability 
to be an “agent of self-transformation,” and are instead a “passive patient of transforming 
powers.”
146  To the extent that it is limitations that give a person the contours of an identity, that 
identity is lost along with the limitations.
147 
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Cognitive	 ﾠEnhancement	 ﾠUse	 ﾠCan	 ﾠSometimes	 ﾠbe	 ﾠa	 ﾠForm	 ﾠof	 ﾠCheating	 ﾠ	 ﾠ
 
Cognitive enhancement is also considered to be a form of mental cheating.  While it is 
clear that goals are important when it comes to the enhancement debate, means to those goals are 
also important, and can tend to be overlooked.  The manner in which goals are achieved reflects 
values in society that can differ depending on the type of means used.
148 
Parallels are drawn between steroids in sports and drugs to improve attention, memory, or 
motivation around exam time.  However, there are distinctions between physical enhancers and 
cognitive enhancers.  Physical enhancements are most frequently talked about in terms of their 
abuse in sports.  However, sports are a unique type of interaction.  For one, sport is governed by 
rules to ensure a level playing field.  Once enhancements are banned in a sport, then it goes 
beyond a legal norm to a social norm of good sportsmanship and not trying to get an unfair 
advantage over an opponent.  Furthermore, the value gained by sports is largely present in the 
competition itself – we care about how a team wins, not just that they win.  In these areas society 
cares more about the way something is accomplished (the means), while in other areas society 
care more about the accomplishment itself (the goal).
149  Unlike a quarterback, when it comes to 
a surgeon we care much more whether the procedure is successful or not, and less about the 
methods the surgeon had to perform to obtain a successful surgery.   
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Cognitive	 ﾠEnhancement	 ﾠUse	 ﾠCan	 ﾠbe	 ﾠCoercive	 ﾠ
 
Coercion is another serious issue to be considered.  If cognitive enhancements are 
allowed, then that could result in subtle or overt coercion on individuals not taking enhancement 
that they should take them to keep up.  This is especially true in competitive situations where 
competitive advantages are needed in order to take a larger slice of the pie.  However, there are 
plenty of situations in which cognitive enhancement should not be considered a zero sum 
calculus.  For example, cognitive enhancement would likely lead to greater and faster scientific 
achievement.
150 Improvements in scientific development could be aimed at improving moral 
development.
151 Therefore, moral judgments about cognitive enhancers should take into account 
the purpose of the enhancement.
152  Whether an activity is directly competitive has an impact on 
how the moral perspective of cognitive enhancers should be viewed.
153 
Conclusion	 ﾠ
 
The current hype about cognitive enhancers largely oversells what current drugs have been 
shown capable of doing.  However, the field is one of tremendous interest and growth, and the 
FDA may not have the luxury much longer of being able to avoid confronting highly effective, 
safe drugs that can show substantial cognitive improvement in normal individuals.  Once these 
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drugs become viable, the range of ethical dilemmas presented in this paper, among others, will 
land in the lap of FDA regulators trying to determine how to handle regulation of these drugs.  
To a certain extent, the problem may continue to be kicked down the road for a time due to the 
ability of pharmaceutical companies to narrowly target these drugs for some indication and then 
rely on off-label use.  The 90% rate of off-label use of Provigil suggests that this may be the 
default route.  However, when off-label uses become this prevalent and represent such a large 
percentage of a companies’ profits, industry will be especially vulnerable to liability under the 
objective intent standard.  Ultimately, the question the FDA and society has to address is whether 
the current system of ignoring and pretending away the reality of use will be satisfactory when 
the next generation of enhancement drugs rolls around.  I argue that this system only heightens 
the safety and inequality concerns associated with cognitive enhancing drugs, and that a new 
framework for evaluation is the only way these concerns can be thoughtfully addressed. 